Head-to-head evidence
Gemtuzumab Ozogamicin vs Lintuzumab-Ac225
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD33 · full Acute Myeloid Leukemia pipeline
Gemtuzumab Ozogamicin
Marketed by Pfizer
NCT00052299 · Phase 3 · completed
The trial was randomized and actively controlled, with 472 participants, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT05955261 (registry estimate)
Lintuzumab-Ac225
Developed by Actinium Pharmaceuticals
NCT00006045 · Phase 3 · status unknown
This trial tested combination chemotherapy with or without an antibody therapy (lintuzumab) in patients with relapsed or refractory acute myeloid leukemia, but the public registry record does not state whether treatment assignment was randomized or blinded, and no outcome measures or results are available, so its design rigor and findings cannot be established from what is provided.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gemtuzumab Ozogamicin's landscape · Lintuzumab-Ac225's landscape